Detection and genotype analysis of human papillomavirus in non-small cell lung cancer patients

Tumor Biology

Volumn 35, Issue 4, 2014, Pages 3203-3209

  Sarchianaki, Emmanouela ^a   Derdas, Stavros P ^a   Ntaoukakis, Markos ^a   Vakonaki, Elena ^a   Lagoudaki, Eleni D ^a   Lasithiotaki, Ismini ^b   Sarchianaki, Anna ^a   Koutsopoulos, Anastasios ^a   Symvoulakis, Emmanouil K ^a   Spandidos, Demetrios A ^a   Antoniou, Katerina M ^b   Sourvinos, George ^a  

^a UNIVERSITY OF CRETE   (Greece)

^b UNIVERSITY OF CRETE   (Greece)

Author keywords

Genotypes; HPV; Non small cell lung cancer; Real Time PCR

Indexed keywords

ADENOCARCINOMA; ARTICLE; CONTROLLED STUDY; FEMALE; GENOTYPE; GREECE; HUMAN; HUMAN PAPILLOMAVIRUS DNA TEST; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; UNDIFFERENTIATED CARCINOMA; VIRUS GENOME; WART VIRUS;

AGED; CARCINOMA, NON-SMALL-CELL LUNG; DNA, VIRAL; FEMALE; FORCED EXPIRATORY VOLUME; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; PAPILLOMAVIRIDAE; VITAL CAPACITY;

EID: 84898800911     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-1419-2     Document Type: Article

References (42)

1. Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the Human Development Index (2008-2030): a population-based study. Lancet Oncol. 2012;13:790-801.
2. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet. 1997;349:1498-504.
3. de Villiers E-M, Fauquet C, Broker TR, Bernard H-U, zur Hausen H. Classification of papillomaviruses. Virology. 2004;324:17-27.
4. Bernard HU, Burk RD, Chen Z, van Doorslaer K, zur Hausen H, de Villiers EM. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology. 2010;401:70-9.
5. Muñoz N, Bosch FX, Castellsagué X, Díaz M, de Sanjose S, Hammouda D, et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer. 2004;111:278-85.
6. Parkin DM, Bray F. Chapter 2: The burden of HPV-related cancers. Vaccine. 2006;24:11-25.
7. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol. 2002;55:244-65.
8. Doorbar J. Molecular biology of human papillomavirus infection and cervical cancer. Clin Sci. 2006;110:525-41.
9. Brink AA, Snijders PJ, Meijer CJ, Berkhof J, Verheijen RH. HPV testing in cervical screening. Best Pract Res Clin Obstet Gynaecol. 2006;20:253-66.
10. zur Hausen H. Papillomaviruses causing cancer: evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst. 2000;92:690-8.
11. Munger K, Baldwin A, Edwards KM, Hayakawa H, Nguyen CL, Owens M, et al. Mechanisms of human papillomavirus-induced oncogenesis. J Virol. 2004;78:11451-60.
12. Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Tr B, et al. Global effects of human papillomavirus type 18 E6/E7 in an organotypic keratinocyte culture system. J Virol. 2004;78:9041-50.
13. Syrjanen KJ. HPV infections and lung cancer. J Clin Pathol. 2002;55:885-91.
14. Mammas IN, Sourvinos G, Zaravinos A, Spandidos DA. Vaccination against human papilloma virus (HPV): epidemiological evidence of HPV in non-genital cancers. Pathol Oncol Res. 2011;17:103-19.
15. Klein F, Amin Kotb WF, Petersen I. Incidence of human papilloma virus in lung cancer. Lung Cancer. 2009;65:13-8.
16. Sourvinos G, Mammas IN, Derdas S, Spandidos DA. Human papillomaviruses (HPVs) in lung cancer: a causative trigger or just a co-incidence? Lung Cancer. 2013;79:95-6.
17. Syrjänen K. Detection of human papillomavirus in lung cancer: systematic review and meta-analysis. Anticancer Res. 2012;32:3235-50.
18. Kountouri MP, Mammas IN, Spandidos DA. Human papilloma virus (HPV) in lung cancer: unanswered questions. Lung Cancer. 2010;67:125020.
19. Papadakis ED, Soulitzis N, Spandidos DA. Association of p53 codon 72 polymorphism with advanced lung cancer: the Arg allele is preferentially retained in tumours arising in Arg/Pro germline heterozygotes. Br J Cancer. 2002;87:1013-8.
20. de Araujo M, De Marco L, Santos C, Rubira-Bullen I, Ronco G, Pennini I, et al. GP5+/6+ SYBR Green methodology for simultaneous screening and quantification of human papillomavirus. J Clin Virol. 2009;45:90-5.
21. Roberts CC, Swoyer R, Bryan JT, Taddeo FJ. Comparison of real-time multiplex human papillomavirus (HPV) PCR assays with the linear array HPV genotyping PCR assay and influence of DNA extraction method on HPV detection. J Clin Microbiol. 2011;49:1899-906.
22. Viallet J, Minna JD. Dominant oncogenes and tumor suppressor genes in the pathogenesis of lung cancer. Am J Respir Cell Mol Biol. 1990;2:225-32.
23. Lasithiotaki I, Antoniou KM, Derdas SP, Sarchianaki E, Symvoulakis EK, Psaraki A, et al. The presence of Merkel cell polyomavirus is associated with deregulated expression of BRAF and Bcl-2 genes in non-small cell lung cancer. Int J Cancer. 2013;133:604-11.
24. Antoniou KM, Lasithiotaki I, Symvoulakis E, Derdas SP, Psaraki A, Spandidos DA, et al. Molecular pathological findings of Merkel cell polyomavirus in lung cancer: a possible etiopathogenetic link? Int J Cancer. 2013;133(12):3016-7. doi: 10.1002/ijc.28308.
25. Park MS, Chang YS, Shin JH, Kim DJ, Chung KY, Shin DH, et al. The prevalence of human papillomavirus infection in Korean non-small cell lung cancer patients. Yonsei Med J. 2007;48:69-77.
26. Fei Y, Yang J, Hsieh WC, Wu JY, Wu TC, Goan YG, et al. Different human papillomavirus 16/18 infection in Chinese non-small cell lung cancer patients living in Wuhan, China. Jpn J Clin Oncol. 2006;36:274-9.
27. Cheng YW, Wu MF, Wang J, Yeh KT, Goan YG, Chiou HL, et al. Human papillomavirus 16/18 E6 oncoprotein is expressed in lung cancer and related with p53 inactivation. Cancer Res. 2007;67:10686-93.
28. Tung MC, Wu HH, Cheng YW, Wang L, Chen CY, Yeh SD, et al. Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. Cancer. 2013;119(18):3367-76. doi: 10.1002/cncr.28220.
29. Wang JL, Fang CL, Wang M, Yu MC, Bai KJ, Lu PC, et al. Human papillomavirus infections as a marker to predict overall survival in lung adenocarcinoma. Int J Cancer. 2013. doi: 10.1002/ijc.28349.
30. Hirayasu T, Iwamasa T, Kamada Y, Koyanagi Y, Usuda H, Genka K. Human papillomavirus DNA in squamous cell carcinoma of the lung. J Clin Pathol. 1996;49:810-7.
31. Yu Y, Yang A, Hu S, Yan H. Correlation of HPV-16/18 infection of human papillomavirus with lung squamous cell carcinomas in Western China. Oncol Rep. 2009;21:1627-32.
32. Wang Y, Wang A, Jiang R, Pan H, Huang B, Lu Y, et al. Human papillomavirus type 16 and 18 infection is associated with lung cancer patients from the central part of China. Oncol Rep. 2008;20:333-9.
33. Goto A, Li CP, Ota S, Niki T, Ohtsuki Y, Kitajima S, et al. Human papillomavirus infection in lung and esophageal cancers: analysis of 485 Asian cases. J Med Virol. 2011;83:1383-90.
34. Chen SP, Hsu NY, Wu JY, Chen CY, Chou MC, Lee H, et al. Association of p53 codon 72 genotypes and clinical outcome in human papillomavirus-infected lung cancer patients. Ann Thorac Surg. 2013;95:1196-203.
35. Tung MC, Wu HH, Cheng YW, Wang L, Chen CY, Yeh SD, et al. Association of epidermal growth factor receptor mutations with human papillomavirus 16/18 E6 oncoprotein expression in non-small cell lung cancer. Cancer. 2013;119:3367-76.
36. Cheng Y, Chiou H, Sheu GT, Hsieh LL, Chen CY, Su JM, et al. The association of human papillomavirus 16/18 infection with lung cancer among nonsmoking Taiwanese women. Cancer Res. 2001;61:2799-803.
37. Chiou HL, Wu MF, Liaw YC, Cheng YW, Wong RH, Chen CY, et al. The presence of human papillomavirus type 16/18 DNA in blood circulation may act as a risk marker of lung cancer in Taiwan. Cancer. 2003;97:1558-63.
38. Cheng YW, Chiou HL, Chen JT, Chou MC, Lin TS, Lai WW, et al. Gender difference in human papillomavirus infection for non-small cell lung cancer in Taiwan. Lung Cancer. 2004;46:165-70.
39. Kato T, Koriyama C, Khan N, Samukawa T, Yanagi M, Hamada T, et al. EGFR mutations and human papillomavirus in lung cancer. Lung Cancer. 2012;78:144-7.
40. Baba M, Castillo A, Koriyama C, Yanagi M, Matsumoto H, Natsugoe S, et al. Human papillomavirus is frequently detected in gefitinib-responsive lung adenocarcinomas. Oncol Rep. 2010;23:1085-92.
41. Carpagnano GE, Koutelou A, Natalicchio MI, Martinelli D, Ruggieri C, Di Taranto A, et al. HPV in exhaled breath condensate of lung cancer patients. Br J Cancer. 2011;105:1183-90.
42. Lee SH, Vigliotti VS, Vigliotti JS, Pappu S. Routine human papillomavirus genotyping by DNA sequencing in community hospital laboratories. Infect Agent Cancer. 2007;2:1-11.